Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Damond

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Bulletin De La Societe De Pathologie Exotique (1990)|November 26, 1999
[Variability of human immunodeficiency virus type 1]F Brun-Vézinet, F Damond, F Simon
Pathologie-Biologie|May 31, 2008
[HIV genetic diversity and its consequences]B Roquebert, F Damond, F Brun-Vézinet, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|January 9, 2018
Corrigendum to "HIV-2 molecular epidemiology" [Infect. Genet. Evol. 46 (2016) 233-240]B Visseaux, F Damond, S Matheron, et al.
AIDS (London, England)|April 15, 1999
HIV-1 subtypes and plasma RNA quantificationF Damond, C Apetrei, D Descamps, et al.
AIDS (London, England)|July 14, 1998
Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitorsD Descamps, C Apetrei, G Collin, et al.
Journal of Clinical Microbiology|February 7, 2008
Plasma load discrepancies between the Roche Cobas Amplicor human immunodeficiency virus type 1 (HIV-1) Monitor version 1.5 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 assaysJoseph D C Yao, Jeffrey J Germer, F Damond, et al.
Journal of Clinical Microbiology|September 28, 2001
V3 serological subtyping of human immunodeficiency virus type 2 infection is not relevantJ C Plantier, F Damond, S Souquières, et al.
AIDS Research and Human Retroviruses|October 10, 1996
HIV type 1 diversity in northern Paris, FranceF Simon, I Loussert-Ajaka, F Damond, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1996
Response to fluconazole by 23 patients with human immunodeficiency virus infection and oral candidiasis: pharmacological and mycological factorsF Lacassin, F Damond, C Chochillon, et al.
AIDS (London, England)|December 1, 1996
Lack of screening test sensitivity during HIV-1 non-subtype B seroconversionsC Apetrei, I Loussert-Ajaka, D Descamps, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Bulletin De La Societe De Pathologie Exotique (1990)|November 26, 1999
[Variability of human immunodeficiency virus type 1]F Brun-Vézinet, F Damond, F Simon
Pathologie-Biologie|May 31, 2008
[HIV genetic diversity and its consequences]B Roquebert, F Damond, F Brun-Vézinet, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|January 9, 2018
Corrigendum to "HIV-2 molecular epidemiology" [Infect. Genet. Evol. 46 (2016) 233-240]B Visseaux, F Damond, S Matheron, et al.
AIDS (London, England)|April 15, 1999
HIV-1 subtypes and plasma RNA quantificationF Damond, C Apetrei, D Descamps, et al.
AIDS (London, England)|July 14, 1998
Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitorsD Descamps, C Apetrei, G Collin, et al.
Journal of Clinical Microbiology|February 7, 2008
Plasma load discrepancies between the Roche Cobas Amplicor human immunodeficiency virus type 1 (HIV-1) Monitor version 1.5 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 assaysJoseph D C Yao, Jeffrey J Germer, F Damond, et al.
Journal of Clinical Microbiology|September 28, 2001
V3 serological subtyping of human immunodeficiency virus type 2 infection is not relevantJ C Plantier, F Damond, S Souquières, et al.
AIDS Research and Human Retroviruses|October 10, 1996
HIV type 1 diversity in northern Paris, FranceF Simon, I Loussert-Ajaka, F Damond, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1996
Response to fluconazole by 23 patients with human immunodeficiency virus infection and oral candidiasis: pharmacological and mycological factorsF Lacassin, F Damond, C Chochillon, et al.
AIDS (London, England)|December 1, 1996
Lack of screening test sensitivity during HIV-1 non-subtype B seroconversionsC Apetrei, I Loussert-Ajaka, D Descamps, et al.
Pageof 4